Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) of the October 29, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you invested in Sarepta stock or options between September 6, 2017 and August 19, 2019 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org.
The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Sarepta securities between September 6, 2017 and August 19, 2019 (the “Class Period”). The case, Salinger v. Sarepta Therapeutics, Inc., No.19-cv-08122 was filed on August 30, 2019.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by making materially false and misleading statements regarding Sarepta’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) golodirsen posed significant safety risks to patients; (2) consequently, the NDA package for golodirsen’s accelerated approval was unlikely to receive FDA approval; and (3) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.
On August 19, 2019, post-market, Sarepta announced receipt of a Complete Response Letter (“CRL”) from the FDA regarding the Company’s NDA seeking accelerated approval of golodirsen for the treatment of DMD. Sarepta disclosed that “[t]he CRL generally cites two concerns: the risk of infections related to intravenous infusion ports and renal toxicity seen in pre-clinical models of golodirsen and observed following administration of other antisense oligonucleotides.”
On this news, Sarepta’s stock fell from $120.31 on August 19, 2019 to $102.07 on August 20, 2019—an $18.24 or 15.16% drop.
Sarepta Therapeutics, Inc. (SRPT)
* The submission of this form does not create an attorney-client relationship.
Filed on 09/04/2019
Ticker NASDAQ: SRPT
Lead Plaintiff Deadline 10/29/2019
38 days remaining
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
Richard W. Gonnello email@example.com Phone (212) 983-9330 Fax (212) 983-9331